The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Key Points NPM1 RT-PCR levels >1% are associated with poor overall and disease-free survival in AML patients treated with chemotherapy. NPM1 MRD levels >10% are associated with poor overall and disease-free survival in AML patients after allogeneic transplantation.

Download Full-text

α(1,6)Fucosyltransferase expression is an independent prognostic factor for disease-free survival in colorectal carcinoma

Human Pathology ◽

10.1016/j.humpath.2011.01.021 ◽

2011 ◽

Vol 42 (11) ◽

pp. 1740-1750 ◽

Cited By ~ 15

Author(s):

L. Muinelo-Romay ◽

S. Villar-Portela ◽

E. Cuevas Alvarez ◽

E. Gil-Martín ◽

Almudena Fernández-Briera

Keyword(s):

Prognostic Factor ◽

Colorectal Carcinoma ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

Free Survival ◽

Disease Free

Download Full-text

Expression of EEF1A1 Is Associated with Prognosis of Patients with Colon Adenocarcinoma

Journal of Clinical Medicine ◽

10.3390/jcm8111903 ◽

2019 ◽

Vol 8 (11) ◽

pp. 1903 ◽

Cited By ~ 3

Author(s):

Eun kyo Joung ◽

Jiyoung Kim ◽

Nara Yoon ◽

Lee-so Maeng ◽

Ji Hoon Kim ◽

...

Keyword(s):

Colon Cancer ◽

Multivariate Analysis ◽

Prognostic Factor ◽

Cox Regression ◽

Disease Free Survival ◽

Colon Adenocarcinoma ◽

Independent Prognostic Factor ◽

Free Survival ◽

Cox Regression Analysis ◽

Disease Free

Background: The prognostic role of the translational factor, elongation factor-1 alpha 1 (EEF1A1), in colon cancer is unclear. Objectives: The present study aimed to investigate the expression of EEF1A in tissues obtained from patients with stage II and III colon cancer and analyze its association with patient prognosis. Methods: A total of 281 patients with colon cancer who underwent curative resection were analyzed according to EEF1A1 expression. Results: The five-year overall survival in the high-EEF1A1 group was 87.7%, whereas it was 65.6% in the low-EEF1A1 expression group (hazard ratio (HR) 2.47, 95% confidence interval (CI) 1.38–4.44, p = 0.002). The five-year disease-free survival of patients with high EEF1A1 expression was 82.5%, which was longer than the rate of 55.4% observed for patients with low EEF1A1 expression (HR 2.94, 95% CI 1.72–5.04, p < 0.001). Univariate Cox regression analysis indicated that age, preoperative carcinoembryonic antigen level, adjuvant treatment, total number of metastatic lymph nodes, and EEF1A1 expression level were significant prognostic factors for death. In multivariate analysis, expression of EEF1A1 was an independent prognostic factor associated with death (HR 3.01, 95% CI 1.636–5.543, p < 0.001). EEF1A1 expression was also an independent prognostic factor for disease-free survival in multivariate analysis (HR 2.54, 95% CI 1.459–4.434, p < 0.001). Conclusions: Our study demonstrated that high expression of EEF1A1 has a favorable prognostic effect on patients with colon adenocarcinoma.

Download Full-text

Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.590 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. 590-590 ◽

Cited By ~ 1

Author(s):

Shinichiro Yamada ◽

Mitsuo Shimada ◽

Yuji Morine ◽

Satoru Imura ◽

Tetsuya Ikemoto ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Prognostic Factor ◽

Prognostic Score ◽

Univariate Analysis ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

Tumor Diameter ◽

Free Survival ◽

Significant Difference ◽

Disease Free

590 Background: An aging society has come, and “Frailty” is becoming increasingly important in surgery. Recently, clinical frail scale (CFS), which is simple criteria for frailty, has been reported to be useful for prognostic prediction of non-cardiac surgery (Ann Surg. 2018). Herein we report a new knowledge about frailty for patients with hepatocellular carcinoma (HCC) undergoing hepatectomy. Methods: Eighty-one patients over 75 years who underwent hepatectomy for HCC between 2007 and 2018 were enrolled in this study. Frailty was diagnosed as CFS≥4, and patient were divided into 2 groups, frailty (n = 17) and no frailty (n = 64). Clinicopathological factors were compared between 2 groups. Results: Patients’ background, such as age, gender, preoperative comorbidity, and liver function showed no significant difference between 2 groups. Regarding tumor factors, frailty group showed significant larger tumor diameter, more advanced stage (p < 0.05) and tendency of high PIVKA-II (p = 0.15) compared with no frailty group. Frailty group showed significant high CRP level (p < 0.01), high modified Glasgow prognostic score (mGPS, p = 0.04) and tendency of high neutrophil-lymphocyte ratio (NLR, p = 0.14). Frailty group also showed tendency of higher rate of postoperative complication (p = 0.11) and longer postoperative hospital stay (p = 0.09). Overall and disease-free survival rate were significantly worse in frailty group (p = 0.03). In univariate analysis for overall survival, AFP≥10, PIVKA-II≥400, frailty and mGPS high (1, 2) were prognostic factor. Multivariate analysis revealed that frailty was independent prognostic factor. In univariate analysis of disease-free survival, only frailty was detected as prognostic factor. Conclusions: Frailty is an independent prognostic factor for HCC patients who underwent hepatectomy.

Download Full-text

Influence of Androgen Receptor on the Prognosis of Breast Cancer

Journal of Clinical Medicine ◽

10.3390/jcm9041083 ◽

2020 ◽

Vol 9 (4) ◽

pp. 1083 ◽

Cited By ~ 1

Author(s):

Ki-Tae Hwang ◽

Young A Kim ◽

Jongjin Kim ◽

Jeong Hwan Park ◽

In Sil Choi ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Androgen Receptor ◽

Prognostic Factor ◽

Cancer Patients ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

Breast Cancer Patients ◽

Free Survival ◽

Disease Free

We investigated the prognostic influence of androgen receptor (AR) on breast cancer. AR status was assessed using immunohistochemistry with tissue microarrays from 395 operable primary breast cancer patients who received curative surgery. The Kaplan–Meier estimator was used to analyze the survival rates and a log-rank test was used to determine the significance of the differences in survival. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and the 95% confidence interval (CI) of survival. There were 203 (51.4%) subjects with a low expression of AR, and 192 patients (48.6%) with a high expression rate. The high AR expression group showed superior overall survival (p = 0.047) and disease-free survival (p = 0.004) when compared with the low AR expression group. The high AR expression group showed superior systemic recurrence-free survival when compared with the low AR expression group (p = 0.027). AR was an independent prognostic factor for both overall survival (HR, 0.586; 95% CI, 0.381–0.901; p = 0.015) and disease-free survival (HR, 0.430; 95% CI, 0.274–0.674; p < 0.001). A high AR expression was a significant favorable prognostic factor only in the subgroups with positive hormone receptors (HRc) and negative human epidermal growth factor receptor 2 (HER2) when considering disease-free survival (p = 0.026). The high AR expression group was significantly associated with superior overall survival and disease-free survival when compared with the low AR expression group with breast cancer patients. AR was a significant independent prognostic factor for both overall survival and disease-free survival. The prognostic impact of AR was valid in the HRc(+)/HER2(−) subtype when considering disease-free survival. These findings suggest the clinical usefulness of AR as a prognostic marker of breast cancer in clinical settings.

Download Full-text

Age as a prognostic factor for recurrence in premenopausal breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e11036 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e11036-e11036

Author(s):

Antonia Perello ◽

Gemma Clemente ◽

Jose Duran ◽

Bartomeu Colom ◽

Carmen Garcias-Espana ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Young Patients ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

Age At Diagnosis ◽

Free Survival ◽

Premenopausal Patients ◽

Disease Free

e11036 Background: It remains controversial if young age at diagnosis is an independent prognostic factor for recurrence in breast cancer (BC) patients. Data regarding recurrence with long-term follow-up in premenopausal women are sparse. The aim of the study was to compare the outcome of young patients (<=39 years) with older premenopausal patients. Methods: We collected clinical and pathological data from an inception cohort of 241 premenopausal patients aged <=50 years at diagnosis with stage I-III BC between January 2000 and December 2005 in a single institution. Disease-free survival (DFS) event was defined as time from diagnosis to local or distant recurrence, contralateral invasive BC or death from any cause. Kaplan-Meier curves and Cox model were used to analyze the covariable predictors for recurrence. Results: Median age was 43 years (range: 24-50) and median follow-up was 100 months (range: 72-137). Seventy seven patients (32%) were <=39 and 164 (68%) >39 years of age at diagnosis. Five and 10-year disease-free survival rate was 61 % and 48% respectively for the younger group and 77% and 74% for the older group (p<0.001). In the univariate analysis the hazard ratio (HR) for recurrence in young patients was 2.16 (95%CI: 1.38-3.37) (p< 0.001) Adjusting for T stage (<=2 cm versus >2 cm), N (negative versus positive nodes), Grade (grade 1-2 versus grade 3) and Hormonal Receptor status (positive versus negative), age less than 40 remains and independent prognostic factor for recurrence with an adjusted HR of 2.42 (95%CI: 1.42-4.10) (p<0.001), and was the most important adverse independent predictor among the factors included in the model. Conclusions: BC patients younger than 40 years of age at diagnosis have worse prognosis than older premenopausal patients, and have an independent prognostic value for recurrence after adjusting for known prognostic factors.

Download Full-text

Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)

BJU International ◽

10.1111/bju.12067 ◽

2013 ◽

Vol 111 (8) ◽

pp. E348-E353 ◽

Cited By ~ 45

Author(s):

Michela de Martino ◽

Tobias Klatte ◽

Christoph Seemann ◽

Matthias Waldert ◽

Andrea Haitel ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prognostic Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

C Reactive Protein ◽

Free Survival ◽

Reactive Protein ◽

Disease Free

Download Full-text

Ratio Between Positive Lymph Nodes and Total Dissected Axillaries Lymph Nodes as an Independent Prognostic Factor for Disease-Free Survival in Patients With Breast Cancer

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000071941.70772.dc ◽

2004 ◽

Vol 27 (3) ◽

pp. 304-306 ◽

Cited By ~ 41

Author(s):

Luciano Jos?? Megale Costa ◽

Heloisa Prado Soares ◽

Heloisa Amaral Gaspar ◽

Luciana Garcia Trujillo ◽

Patr??cia Xavier Santi ◽

...

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Lymph Nodes ◽

Disease Free Survival ◽

Independent Prognostic Factor ◽

Free Survival ◽

Disease Free ◽

Positive Lymph Nodes

Download Full-text

Prognostic Value of the Hemoglobin/Red Cell Distribution Width Ratio in Resected Lung Adenocarcinoma

Cancers ◽

10.3390/cancers13040710 ◽

2021 ◽

Vol 13 (4) ◽

pp. 710

Author(s):

Francesco Petrella ◽

Monica Casiraghi ◽

Davide Radice ◽

Andrea Cara ◽

Gabriele Maffeis ◽

...

Keyword(s):

Prognostic Factor ◽

Lung Adenocarcinoma ◽

Disease Free Survival ◽

Red Cell Distribution Width ◽

Red Cell ◽

Cell Distribution ◽

Distribution Width ◽

Free Survival ◽

Node Involvement ◽

Disease Free

Background: The ratio of hemoglobin to red cell distribution width (HRR) has been described as an effective prognostic factor in several types of cancer. The aim of this study was to investigate the prognostic role of preoperative HRR in resected-lung-adenocarcinoma patients. Methods: We enrolled 342 consecutive patients. Age, sex, surgical resection, adjuvant treatments, pathological stage, preoperative hemoglobin, red cell distribution width, and their ratio were recorded for each patient. Results: Mean age was 66 years (SD: 9.0). There were 163 females (47.1%); 169 patients (49.4%) had tumors at stage I, 71 (20.8%) at stage II, and 102 (29.8%) at stage III. In total, 318 patients (93.0%) underwent lobectomy, and 24 (7.0%) pneumonectomy. Disease-free survival multivariable analysis disclosed an increased hazard ratio (HR) of relapse for preoperative HRR lower than 1.01 (HR = 2.20, 95%CI: (1.30–3.72), p = 0.004), as well as for N1 single-node (HR = 2.55, 95%CI: (1.33–4.90), p = 0.005) and multiple-level lymph node involvement compared to N0 for both N1 (HR = 9.16, 95%CI:(3.65–23.0), p < 0.001) and N2 (HR = 10.5, 95%CI:(3.44–32.2, p < 0.001). Conclusion: Pre-operative HRR is an effective prognostic factor of disease-free survival in resected-lung-adenocarcinoma patients, together with the level of pathologic node involvement.

Download Full-text